Rigel Pharmaceuticals (RIGL) Revenue (2010 - 2026)

Rigel Pharmaceuticals' Revenue history runs 16 years deep, the most recent figure standing at $58.8 million for Q1 2026.

• On a quarterly basis, Revenue rose 10.28% year-over-year to $58.8 million in Q1 2026; TTM through Mar 2026 was $299.8 million, a 47.61% increase from a year earlier, with the FY2025 full-year figure at $294.3 million, up 64.15% from the prior year.
• Revenue eased to $58.8 million in Q1 2026 per RIGL's latest filing, from $69.8 million in the prior quarter.
• Across five years, Revenue topped out at $101.7 million in Q2 2025 and bottomed at $16.7 million in Q1 2022.
• The 5-year median for Revenue is $36.8 million (2024), against an average of $45.3 million.
• Across the five-year window, Revenue tumbled 79.34% in 2022 and jumped 176.01% in 2025, its largest moves.
• Year by year, Revenue stood at $51.3 million in 2022, then sank by 30.2% to $35.8 million in 2023, then jumped by 60.92% to $57.6 million in 2024, then advanced by 21.19% to $69.8 million in 2025, then dropped by 15.74% to $58.8 million in 2026.
• Per Business Quant, the three latest RIGL Revenue figures stand at $58.8 million (Q1 2026), $69.8 million (Q4 2025), and $69.5 million (Q3 2025).